A Dengue Vaccine.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27368091.
- Also identified by DOI 10.1016/j.cell.2016.06.036.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Denvaxia is the first licensed vaccine for the prevention of dengue. It is a live vaccine developed using recombinant DNA technology. The vaccine is given as three doses over the course of a year and has the potential to prevent hundreds of thousands of hospitalizations each year.
Medical subject headings
- Dengue
- Dengue Vaccines